PI-3 Kinase-PTEN signaling node

An intercept point for the control of angiogenesis

R. C. Castellino, C. R. Muh, Donald L Durden

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Angiogenesis is tightly regulated by opposing mechanisms in mammalian cells and is controlled by the angiogenic switch. Other review articles have described a central role for the PTEN/PI-3 kinase/AKT signaling node in the coordinate control of cell division, tumor growth, apoptosis, invasion and cellular metabolism [1, 2]. In this review, we focus on literature that supports the PTEN/PI-3 kinase/AKT signaling node as a major control point for the angiogenic switch in both the on and off positions. We also discuss the rationale for designing small molecule drugs that target the PTEN/PI-3 kinase/AKT signaling node for therapeutic intervention. Our hypothesis is that, instead of inhibiting one cell surface receptor, such as VEGFR2 with bevacizumab (Avastin®), thereby leaving a significant number of receptors free to pulse angiogenic signals, a more effective strategy may be to regulate signaling through an intercept node where redundant cell surface receptor signals converge to transmit important signaling events within the cell. This therapeutic configuration brings coordinate control over multiple cell surface receptors in concert with a physiologic response which may combine arrest of cell cycle progression with growth inhibition and the induction of genes involved in specialized functions such as movement, which are all required for the complex process of angiogenesis to occur in a temporal-spatial paradigm.

Original languageEnglish (US)
Pages (from-to)380-388
Number of pages9
JournalCurrent Pharmaceutical Design
Volume15
Issue number4
DOIs
StatePublished - May 25 2009

Fingerprint

Cell Surface Receptors
Phosphatidylinositol 3-Kinases
Growth
Cell Cycle Checkpoints
Cell Division
Apoptosis
Therapeutics
Pharmaceutical Preparations
Genes
Neoplasms
Bevacizumab

Keywords

  • AKT
  • Angiogenesis
  • PI-3 kinase
  • PTEN
  • Signaling node

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

PI-3 Kinase-PTEN signaling node : An intercept point for the control of angiogenesis. / Castellino, R. C.; Muh, C. R.; Durden, Donald L.

In: Current Pharmaceutical Design, Vol. 15, No. 4, 25.05.2009, p. 380-388.

Research output: Contribution to journalReview article

@article{caf3cfe0e1c14ffa92406132b0f15281,
title = "PI-3 Kinase-PTEN signaling node: An intercept point for the control of angiogenesis",
abstract = "Angiogenesis is tightly regulated by opposing mechanisms in mammalian cells and is controlled by the angiogenic switch. Other review articles have described a central role for the PTEN/PI-3 kinase/AKT signaling node in the coordinate control of cell division, tumor growth, apoptosis, invasion and cellular metabolism [1, 2]. In this review, we focus on literature that supports the PTEN/PI-3 kinase/AKT signaling node as a major control point for the angiogenic switch in both the on and off positions. We also discuss the rationale for designing small molecule drugs that target the PTEN/PI-3 kinase/AKT signaling node for therapeutic intervention. Our hypothesis is that, instead of inhibiting one cell surface receptor, such as VEGFR2 with bevacizumab (Avastin{\circledR}), thereby leaving a significant number of receptors free to pulse angiogenic signals, a more effective strategy may be to regulate signaling through an intercept node where redundant cell surface receptor signals converge to transmit important signaling events within the cell. This therapeutic configuration brings coordinate control over multiple cell surface receptors in concert with a physiologic response which may combine arrest of cell cycle progression with growth inhibition and the induction of genes involved in specialized functions such as movement, which are all required for the complex process of angiogenesis to occur in a temporal-spatial paradigm.",
keywords = "AKT, Angiogenesis, PI-3 kinase, PTEN, Signaling node",
author = "Castellino, {R. C.} and Muh, {C. R.} and Durden, {Donald L}",
year = "2009",
month = "5",
day = "25",
doi = "10.2174/138161209787315873",
language = "English (US)",
volume = "15",
pages = "380--388",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - PI-3 Kinase-PTEN signaling node

T2 - An intercept point for the control of angiogenesis

AU - Castellino, R. C.

AU - Muh, C. R.

AU - Durden, Donald L

PY - 2009/5/25

Y1 - 2009/5/25

N2 - Angiogenesis is tightly regulated by opposing mechanisms in mammalian cells and is controlled by the angiogenic switch. Other review articles have described a central role for the PTEN/PI-3 kinase/AKT signaling node in the coordinate control of cell division, tumor growth, apoptosis, invasion and cellular metabolism [1, 2]. In this review, we focus on literature that supports the PTEN/PI-3 kinase/AKT signaling node as a major control point for the angiogenic switch in both the on and off positions. We also discuss the rationale for designing small molecule drugs that target the PTEN/PI-3 kinase/AKT signaling node for therapeutic intervention. Our hypothesis is that, instead of inhibiting one cell surface receptor, such as VEGFR2 with bevacizumab (Avastin®), thereby leaving a significant number of receptors free to pulse angiogenic signals, a more effective strategy may be to regulate signaling through an intercept node where redundant cell surface receptor signals converge to transmit important signaling events within the cell. This therapeutic configuration brings coordinate control over multiple cell surface receptors in concert with a physiologic response which may combine arrest of cell cycle progression with growth inhibition and the induction of genes involved in specialized functions such as movement, which are all required for the complex process of angiogenesis to occur in a temporal-spatial paradigm.

AB - Angiogenesis is tightly regulated by opposing mechanisms in mammalian cells and is controlled by the angiogenic switch. Other review articles have described a central role for the PTEN/PI-3 kinase/AKT signaling node in the coordinate control of cell division, tumor growth, apoptosis, invasion and cellular metabolism [1, 2]. In this review, we focus on literature that supports the PTEN/PI-3 kinase/AKT signaling node as a major control point for the angiogenic switch in both the on and off positions. We also discuss the rationale for designing small molecule drugs that target the PTEN/PI-3 kinase/AKT signaling node for therapeutic intervention. Our hypothesis is that, instead of inhibiting one cell surface receptor, such as VEGFR2 with bevacizumab (Avastin®), thereby leaving a significant number of receptors free to pulse angiogenic signals, a more effective strategy may be to regulate signaling through an intercept node where redundant cell surface receptor signals converge to transmit important signaling events within the cell. This therapeutic configuration brings coordinate control over multiple cell surface receptors in concert with a physiologic response which may combine arrest of cell cycle progression with growth inhibition and the induction of genes involved in specialized functions such as movement, which are all required for the complex process of angiogenesis to occur in a temporal-spatial paradigm.

KW - AKT

KW - Angiogenesis

KW - PI-3 kinase

KW - PTEN

KW - Signaling node

UR - http://www.scopus.com/inward/record.url?scp=64249126008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249126008&partnerID=8YFLogxK

U2 - 10.2174/138161209787315873

DO - 10.2174/138161209787315873

M3 - Review article

VL - 15

SP - 380

EP - 388

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 4

ER -